Epigenetik Düzenlemenin Kanser Üzerine Etkileri

Yıl 2021, Cilt: 5 Sayı: 1, 1 - 7, 30.04.2021

Muhammet Mesut Nezir Engin , Esra Özen Engin Recep Eröz , Gorkem Dulger , Hüseyin Yüce

https://doi.org/10.34084/bshr.869351

Öz

Epigenetik DNA dizisindeki değişikliklerden kaynaklanmayan, ama aynı zamanda kalıtsal olan gen ekspresyon değişikliklerini inceleyen biyoloji bilim dalıdır. Epigenetiğin moleküler temeli karmaşık bir olaydır ve belli genlerin ne zaman ve nasıl aktive edileceğini belirler. Kanser, hücrelerin kontrolsüz bir şekilde çoğaldığı ve daha sonra yayıldığı bir hastalık olarak karakterize edilir. Kanser, genetik ve / veya epigenetik değişikliklerin birikmesinin neden olduğu multifaktöryel bir hastalıktır. Epigenetik mekanizmalar, DNA metilasyonu, histon modifikasyonları ve kodlanmayan ribonükleik asit regülasyonunu içerir. Epigenetik mekanizmalar tümör davranışını ve dolayısıyla klinik seyri etkiler. Tanı, tedavi ve prognozu belirleyecek bir biyobelirteç olması ileride birçok kanserin tanı ve tedavisinde kullanılmasını sağlayacaktır. Epigenetik mekanizmalar ile kanser arasındaki ilişkiye yönelik ileride yapılacak çalışmaların kanser tedavisi için umut olacağına inanıyoruz.

Anahtar Kelimeler

Epigenetik, Kanser, DNA Metilasyonu, Histon Modifikasyonları, Kodlanmayan RNA'lar

Effects of Epigenetic Regulation on Cancer

Öz

Epigenetics is the science of biology that studies gene expression changes, which are not caused by changes in DNA sequence, but are also inherited. The molecular basis of epigenetics is a complex phenomenon and determines when and how certain genes are activated. Cancer is characterized as a disease in which cells reproduce uncontrollably and then spread. Cancer is a multifactorial complex disease caused by the accumulation of genetic and/or epigenetic changes. Epigenetic mechanisms include DNA methylation, histone modifications, and noncoding ribonucleic acid regulation. Epigenetic mechanisms affect the tumor behavior and thus the clinical course. Being a biomarker that will determine the diagnosis, treatment and prognosis will enable its use in the diagnosis and treatment of many cancers in the future. We believe that future studies on the relationship between epigenetic mechanisms and cancer will be hope for cancer treatment.

Anahtar Kelimeler

Epigenetic, Cancer, DNA Methylation, Histone Modifications, Non-coding RNAs

Kaynakça

• 1) Seo JY, Park YJ, Yi YA, Hwang JY, Lee IB, Cho BH, et al. Epigenetics:general characteristics and implications for oral health. Restor Dent Endod 2015;40(1):14-22.
• 2) Meissner A, Mikkelsen TS, Gu H, Wernig M, Hanna J, Sivachenko A, et al. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature 2008; 454(7205):766-770.
• 3) Bond DM, Finnegan EJ. Passing the message on: inheritance of epigenetic traits. Trends Plant Sci 2007; 12(5):211-216.
• 4) Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol 2010; 28(10):1057-1068.
• 5) Herman JG, Baylin SB. Gene Silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349(21):2042-2054.
• 6) Jones PA, Baylin SB. The fundemental role of epigenetic events in cancer. Nat Rev Genet 2002; 3(6):415-428.
• 7) Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128(4):683-692.
• 8) Asano T. Drug Resistance in Cancer Therapy and the Role of Epigenetics. J Nippon Med Sch. 2020;87(5):244-251.
• 9) Kanwal R, Gupta S. Epigenetic modifications in cancer. Clin Genet 2012;81(4):303-11.
• 10) Sawan C, Vaissiere T, Murr R, Herceg Z. Epigenetic drivers and genetic passengers on the road to cancer. Mutat Res 2008;642(1-2):1- 13.
• 11) Gürel Ç, Nursal AF, Yiğit S. Epigenetics and Cancer. Turkiye Klinikleri J Radiat Oncol-Special Topics 2016;2(1):45-51.
• 12) Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004; 4(2):143-153.
• 13) Ehrlich M. DNA methylation in cancer: to much, but also too little. Oncogene 2002; 21(35):5400- 5413.
• 14) Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358(11):1148-1159.
• 15) Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC et all. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Research. 2004;64:1975-1986.
• 16) Jeronimo C, Varzim G, Henrique R, Oliveria J, Bento MJet all. I105V polymorphism and promoter methylation of the GSTP1 gene in prostate adenocarcinoma. Cancer Epidemiology, Biomarkers ve Prevention. 2002;11:445-450.
• 17) Qu Y, Dang S, Hou P. Gene methylation in gastric cancer. Clin Chim Acta 2013;424:53- 65.
• 18) Kim YI, Giuliano A, Hatch KD, Schneider A, Nour MA, Dallal GE, et al. Global DNA hypomethylation increses progressively in cervical dysplasia and carcinoma. Cancer 1994; 74(3):893-899.
• 19) Lin CH, Hsieh SY, Sheen IS, Lee WC, Chen TC, Shyu WC, et al. Genome-wide hypomethylation in hepatocellular carcinogenesis. Cancer res 2001; 61(10):4238-4243.
• 20) Bedford MT, van Helden PD. Hypomethylation of DNA in pathological conditions of the human prostate. Cancer Res 1987; 47(20):5274-5276.
• 21) Choi JD, Lee JS. Interplay between epigenetics and genetics in cancer. Genomics Inform 2013;11(4):164-73.
• 22) Mikeska T, Craig JM. DNA methylation biomarkers:cancer and beyond. Genes (Basel) 2014;5(3):821-64.
• 23) Hattori N, Ushijima T. Compendium of aberrant DNA methylation and histone modifications in cancer. Biochem Biophys Res Commun 2014;455(1-2):3-9.
• 24) Subramaniam D, Thombre R, Dhar A, Anant S. DNA methyltransferases:a novel target for prevention and therapy. Front Oncol 2014; 4:80.
• 25) Lewandowska J ,Bartoszek A. DNA methylation in cancer development, diagnosis and therapy--multiple opportunities for genotoxic agents to act as methylome disruptors or remediators. Mutagenesis 2011;26(4):475-87.
• 26) Cohen I, Poreba E, Kamieniarz K, Schneider R. Histone modifiers in cancer: friends or foes? Genes Cancer 2011;2(6):631–647.
• 27) Ellis L, Atadja PW, Johnstone RW. Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther 2009;8(6):1409-20.
• 28) Allfrey VG, Faulkner R, Mirsky AE. Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. Proc. Natl. Acad. Sci. USA 1964;51:786–794.
• 29) Dawson MA, Kouzarides T. Cancer Epigenetics: From Mechanism to Therapy. Cell 2012;150(1):12-27.
• 30) Brait M, Sidransky D. Cancer epigenetics:above and beyond. Toxicol Mech Methods 2011;21(4):275-88.
• 31) Mottamal M, Zheng S, Huang TL, Wang G. Histone deacetylase ınhibitors in clinical studies as templates for new anticancer agents. Molecules 2015;20(3):3898-941.
• 32) Ropero S, Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 2007;1(1):19-25.
• 33) Rajendran P, Williams DE, Ho E, Dashwood RH. Metabolism as a key to histone deacetylase inhibition. Crit Rev Biochem Mol Biol 2011;46(3):181-99.
• 34) Virani S, Colacino JA, Kim JH, Rozek LS. Cancer epigenetics: a brief review. ILAR J 2012;53(3-4):359-69 .
• 35) Lakshmaiah KC, Jacob LA, Aparna S, Lokanatha D, Saldanha SC. Epigenetic therapy of cancer with histone deacetylase inhibitors. J Cancer Res Ther 2014;10(3): 469-78. 36) Ricciuti B, Mecca C, Crino L, Baglivo S, Cenci M, Metro G. Non-coding RNAs in lung cancer. Oncoscience 2014;1(11):674-705.
• 37) Mansoori B, Sandoghchian Shotorbani S, Baradaran B. RNA interference and its role in cancer therapy. Adv Pharm Bull 2014;4(4): 313-21.
• 38) Li PF, Chen SC, Xia T, Jiang XM, Shao YF, Xiao BX, et al. Non-coding RNAs and gastric cancer.World J Gastroenterol 2014;20(18): 5411-9.
• 39) Rönnau CG, Verhaegh GW, Luna-Velez MV, Schalken JA. Noncoding RNAs as novel biomarkers in prostate cancer. Biomed Res Int 2014;2014:591703.
• 40) Li G, Zhang H, Wan X , Yang X, Zhu C, Wang A, et al. Long noncoding RNA plays a key role in metastasis and prognosis of hepatocellular carcinoma. Biomed Res Int 2014;2014: 780521.
• 41) Zhang J, Zhang P, Wang L, Piao HL, Ma L. Long non-coding RNA HOTAIR in carcinogenesis and metastasis. Acta Biochim Biophys Sin (Shanghai) 2014;46(1):1-5.
• 42) Jung G, Illan EH, Moreira L, Balaguer F, Goel A. Epigenetics of colorectal cancer: biomarker and therapeutic potential. Nat Rev Gastroenterol Hepatol. 2020 Feb; 17(2): 111–130.
• 43) Becker PB, Workman JL. Nucleosome Remodeling and Epigenetics. Cold Spring Harb Perspect Biol. 2013;5(9):a017905.
• 44) Nasir A, Bullo MMH, Ahmed Z, Imtiaz A, Yaqoob E, Jadoon M. Nutrigenomics: Epigenetics and cancer prevention: A comprehensive review. Crit Rev Food Sci Nutr. 2020;60(8):1375-1387.